ViewRay Inc, a privately held medical device company, has closed the final tranche of a $45 million round of Series C venture capital financing. Institutional investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors, and Siemens Venture Capital (SVC) GmbH.
The ViewRay system, an image-guided radiation therapy system, provides a patented combination of simultaneous radiotherapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay’s treatment planning and delivery software received 510(k) premarket notification clearance from the US FDA in 2011, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review.
